Azelastine hydrochloride (Synonyms:盐酸氮卓斯汀)
目录号 : KM12181 CAS No. : 79307-93-0 纯度 : 98%

Azelastine hydrochloride 属于抗组胺剂,是一种有效的选择性组胺 1 (H1) 拮抗剂。Azelastine hydrochloride 可用于过敏性鼻炎、哮喘、糖尿病高脂血症和 SARS-CoV-2 的研究。

规格 价格 是否有货 数量
100mg
In-stock
200mg
In-stock
500mg 询价 In-stock
1g 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Azelastine hydrochloridem, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine hydrochloride can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.

体外研究

Azelastine hydrochloride can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling.

Cell Proliferation Assay

Cell Line: Human nasal epithelial cells (HNEpC)
Concentration: 100 μM, 400 μM
Incubation Time: 21 days
Result: Inhibited HNEpC growth.

Western Blot Analysis

Cell Line: Human nasal epithelial cells (HNEpC)
Concentration: 100 μM
Incubation Time: 7 days
Result: Significantly up-regulated the H1R, M1R and M3R levels.
体内研究

Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) significantly reduces blood glucose, HbA1c and serum alkaline phosphatase (ALP), osteocalcin and downregulates apolipoprotein B in diabetic hyperlipidemic rats model.
Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) improves the lipid profile (LDL-c decrease and HDL-c increase) in diabetic hyperlipidemic rats model.
Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) attenuates calcium deposition and aortic calcification in diabetic hyperlipidemic rats model.

Animal Model: Male albino Wistar rats (150-170 g), diabetic hyperlipidemic rats model
Dosage: 4 mg/kg
Administration: Oral administration, daily, for 8 weeks
Result: Ameliorated aortic calcification and increased apolipoprotein A expression along with a decline in apolipoprotein B.
分子式
C22H24N3OCl.HCl
分子量
418.36
CAS号
79307-93-0
中文名称
盐酸氮卓斯汀;盐酸氮斯丁
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (119.51 mM; Need ultrasonic)

H2O : 6.67 mg/mL (15.94 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3903 mL 11.9514 mL 23.9029 mL
5 mM 0.4781 mL 2.3903 mL 4.7806 mL
10 mM 0.2390 mL 1.1951 mL 2.3903 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.98 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.98 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (5.98 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.98 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

临床试验
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
在线客服
咨询热线
400-881-9290
关注微信公众号